株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のトランスレーショナル再生医療市場:2019年〜2029年 - 幹細胞治療・組織エンジニアリング製品・遺伝子治療

Translational Regenerative Medicine Market Forecast 2019-2029: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

発行 Visiongain Ltd 商品コード 209071
出版日 ページ情報 英文 334 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=139.96円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界のトランスレーショナル再生医療市場:2019年〜2029年 - 幹細胞治療・組織エンジニアリング製品・遺伝子治療 Translational Regenerative Medicine Market Forecast 2019-2029: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies
出版日: 2019年02月07日 ページ情報: 英文 334 Pages
概要

当レポートでは、世界のトランスレーショナル再生医療市場について調査分析し、市場予測、地域別の市場予測、二次市場の予測、主要製品、主要企業、SWOT分析、ファイブフォース分析など、体系的な情報を提供しています。

第1章 調査概要

第2章 トランスレーショナル再生医療のイントロダクション

  • 再生医療とは
  • トランスレーショナル再生医療:市場内訳
    • 幹細胞治療
    • 組織エンジニアリング
    • 遺伝子治療
  • 再生医療に対するその他のアプローチ
  • 再生医療の規制
    • 欧州
    • 米国
  • 治験の段階
  • 市場定義

第3章 トランスレーショナル再生医療市場の予測

  • 世界のトランスレーショナル再生医療:市場概要
  • 世界のトランスレーショナル再生医療市場
  • 世界のトランスレーショナル再生医療市場の予測

第4章 幹細胞治療:主な適応

  • 世界の幹細胞治療市場
  • 幹細胞治療:世界市場の予測
  • AlloStem (AlloSource)
  • Osteocel Plus (NuVasive)
  • Trinity ELITE、Trinity Evolution (Orthofix)
  • PureGen (AlphaTec Spine)
  • その他の承認済み幹細胞治療製品
  • 幹細胞治療の開発パイプライン
  • ChondroCelect (TiGenix BV)
  • 幹細胞治療市場:促進要因・抑制要因

第5章 組織エンジニアリング治療:主な適応

  • 世界の組織エンジニアリング治療市場
  • 組織エンジニアリング治療:世界市場予測
  • 創傷修復・治癒における組織エンジニアリング治療
  • 軟骨修復における組織エンジニアリング治療
  • その他の利用可能な組織エンジニアリング治療
  • 組織エンジニアリング治療:開発パイプライン
  • 臓器移植と組織エンジニアリング治療の将来見通し
  • 組織エンジニアリング治療製品市場:促進要因・抑制要因

第6章 遺伝子治療:主な適応

  • 世界の遺伝子治療市場
  • 遺伝子治療:世界市場予測
  • 現在利用可能な遺伝子治療製品
  • 遺伝子治療の開発パイプライン
  • 遺伝子治療市場:促進要因・抑制要因

第7章 主要国のトランスレーショナル再生医療市場の予測

  • トランスレーショナル再生医療市場:地域別
  • 地域別のトランスレーショナル再生医療市場の予測

第8章 北米のトランスレーショナル再生医療市場の予測

  • 米国市場
  • カナダ市場

第9章 欧州のトランスレーショナル再生医療市場の予測

  • 市場概要
  • 市場の成長因子と障壁
  • ドイツ市場
  • フランス市場
  • 英国市場
  • イタリア市場
  • スペイン市場
  • その他

第10章アジア太平洋地域のトランスレーショナル再生医療市場の予測

  • 規制環境
  • 市場の成長因子と障壁
  • 中国市場
  • 日本市場
  • インド市場
  • オーストラリア市場
  • 韓国市場
  • その他

第11章 ラテンアメリカのトランスレーショナル再生医療市場の予測

  • ブラジル市場
  • メキシコ市場
  • その他

第12章 中東・アフリカのトランスレーショナル再生医療市場の予測

  • 湾岸諸国市場
  • 南アフリカ市場
  • その他

第13章 トランスレーショナル再生医療市場における主要企業

  • イントロダクション
  • Athersys, Inc.
  • Avita Medical
  • AxoGen, Inc.
  • MEDIPOST Co., Ltd.
  • NuVasive
  • アステラス製薬
  • Organogenesis Holdings Inc.
  • Osiris Therapeutics, Inc.
  • Pharmicell Co., Ltd.
  • Regenerys Ltd.
  • 武田薬品工業
  • uniQure N.V.
  • Vericel Corporation

第14章 世界のトランスレーショナル再生医療市場の定性分析

  • 市場に影響を与える要因
  • SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • ファイブフォース分析

第15章 結論

図表

List of Tables

  • Table 2.1: European Union Definitions of Regenerative Medicine Products, 2019
  • Table 2.2: Potency and Source of Stem Cells, 2019
  • Table 2.3: Germ Layers and Their Associated Types of Cells and Organs, 2019
  • Table 2.4: Major Types of Stem Cells and Their Properties, 2019
  • Table 2.5: Terminology for Stem Cell Donor-Types, 2019
  • Table 2.6: Clinical Trial Phases, 2019
  • Table 3.1: The Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2017 and 2018
  • Table 3.2: Global Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 3.3: Global Translational Regenerative Medicine Market by Sector: CAGR (%), 2019-2023, 2023-2029, 2019-2029
  • Table 3.4: The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2018, 2023 and 2029
  • Table 3.5: The Global Translational Regenerative Medicine Market: Current Developments in the Field, 2016, 2017 & 2018
  • Table 4.1: Selected Stem Cell Products Currently Available on The Market, 2018
  • Table 4.2: Stages of Osteogenesis, 2018
  • Table 4.3: Global Stem Cell Therapies Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 4.4: Osteocel Plus Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 4.5: Trinity ELITE Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 4.6: TEMCELL / Prochymal Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 4.7: Stem Cell Therapy Pipeline: Therapies in Development, Clinical Trials
  • Table 4.8: Stem Cell Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2018
  • Table 5.1: Selected Tissue Engineering Products Currently Available on the Market, 2018
  • Table 5.2: Global Tissue Engineering Therapies Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 5.3: Apligraf Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 5.4: Dermagraft Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 5.5: Epifix Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 5.6: ReCell Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 5.7: Tissue Engineering Pipeline: Therapies in Development, Clinical Trials
  • Table 5.8: Vital Therapies: Extracorporeal Bio-Artificial Liver Therapy Clinical Trials, 2018
  • Table 6.1: Currently Available Gene Therapy Products, 2018
  • Table 6.2: Global Gene Therapies Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 6.3: Neovasculgen Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 6.4: Glybera Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 6.5: Amgen: Gene Therapy Clinical Trials, 2018
  • Table 6.6: Talimogene Laherparepvec (IMLYGIC) Sales Forecast: Revenues ($m) AGR (%), CAGR (%), 2019-2029
  • Table 6.7: Gene Therapy Pipeline: Therapies in Development, Clinical Trials
  • Table 6.8: Gene Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2018
  • Table 6.9: Advantegene: Gene Therapy Clinical Trials, 2017
  • Table 6.10: Spark Therapeutics: Gene Therapy Clinical Trials, 2018
  • Table 6.11: Recent Developments in Gene Therapy for Use in Diabetes
  • Table 6.12: Gene Therapy Products in the Development Pipeline for Neurological Diseases, 2018
  • Table 7.1: Global Translational Regenerative Medicine Market by Region: Revenue ($m), 2017 and 2018
  • Table 7.2: Global Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 7.3: Global Translational Regenerative Medicine Market by Region: CAGR (%), 2019-2023, 2023-2029, 2019-2029
  • Table 7.4: Global Translational Regenerative Medicine Market by Region: Market Share (%), 2017, 2023, 2029
  • Table 8.1: North America Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017, 2023 and 2029
  • Table 8.2: North America Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 8.3: North America Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 8.4: US Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 8.5: Canada Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 9.1: Europe Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017, 2023 and 2029
  • Table 9.2: Europe Translational Regenerative Medicine Market by Country/Sub-region: Revenue ($m) and Market Share (%), 2017
  • Table 9.3: Europe Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 9.4: Europe Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 9.5: Europe Translational Regenerative Medicine Market by Country/Sub-region: CAGR (%), 2019-2023, 2023-2029, 2019-2029
  • Table 9.6: Germany Translational Regenerative Medicine Market Forecast, 2017-2029 ($m, AGR %, CAGR %)
  • Table 9.7: France Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 9.8: U.K. Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2017-2029
  • Table 9.9: Italy Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2017-2029
  • Table 9.10: Spain Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2017-2029
  • Table 9.11: Rest of Europe Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2017-2029
  • Table 10.1: Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017, 2023 and 2029
  • Table 10.2: Asia-Pacific Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 10.3: Asia-Pacific Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 10.4: China Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2017-2029
  • Table 10.5: Japan Translational Regenerative Medicine Market Forecast: Revenues ($m, AGR %, CAGR %), 2017-2029
  • Table 10.6: India Translational Regenerative Medicine Market Forecast: Revenues ($ m), AGR (%), CAGR (%), 2017-2029
  • Table 10.7: Rest of Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 11.1: Latin America Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017, 2023 and 2029
  • Table 11.2: Latin America Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 11.3: Latin America Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 11.4: Brazil Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 11.5: Mexico Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 11.6: Rest of Latin America Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 12.1: Middle East & Africa Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2017, 2023 and 2029
  • Table 12.2: Middle East & Africa Translational Regenerative Medicine Market Forecast by Sector: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 12.3: Middle East & Africa (MEA) Translational Regenerative Medicine Market Forecast by Country: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 12.4: GCC Countries Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 12.5: South Africa Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 12.6: Middle East & Africa (MEA) Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2017-2029
  • Table 13.1: Athersys, Inc.: Overview, 2019
  • Table 13.2: Athersys, Inc.: Revenue ($m), AGR (%), 2013-2017
  • Table 13.3: Athersys: Regenerative Medicine Clinical Trials, 2018
  • Table 13.4: Avita Medical: Overview, 2019
  • Table 13.5: Avita Medical: Revenue ($m), AGR (%), 2014-2018
  • Table 13.6: Avita Medical: Regenerative Medicine Clinical Trials, 2018
  • Table 13.7: AxoGen, Inc.: Overview, 2019
  • Table 13.8: AxoGen, Inc.: Revenue ($m), AGR (%), 2013-2017
  • Table 13.9: AxoGen, Inc.: Regenerative Medicine Clinical Trials, 2018
  • Table 13.10: MEDIPOST Co., Ltd.: Overview, 2019
  • Table 13.11: MEDIPOST Co., Ltd.: Revenue ($m), AGR (%), 2013-2017
  • Table 13.12: MEDIPOST Co., Ltd.: Regenerative Medicine Clinical Trials, 2018
  • Table 13.13: NuVasive.: Overview, 2019
  • Table 13.14: NuVasive: Revenue ($m), AGR (%), 2013-2017
  • Table 13.15: NuVasive: Regenerative Medicine Clinical Trials, 2018
  • Table 13.16: Astellas Pharma.: Overview, 2019
  • Table 13.17: Astellas Pharma: Revenue ($m), AGR (%), 2013-2017
  • Table 13.18: Astellas Pharma (Ocata Therapeutics): Regenerative Medicine Clinical Trials, 2018
  • Table 13.19: Organogenesis Holdings Inc.: Overview, 2019
  • Table 13.20: Organogenesis Holdings Inc.: Regenerative Medicine Clinical Trials, 2018
  • Table 13.21: Osiris Therapeutics, Inc.: Overview, 2019
  • Table 13.22: Osiris Therapeutics, Inc.: Revenue ($m), AGR (%), 2013-2017
  • Table 13.23: Osiris Therapeutics, Inc.: Regenerative Medicine Clinical Trials, 2018
  • Table 13.24: Pharmicell Co., Ltd.: Overview, 2019
  • Table 13.25: Pharmicell Co., Ltd.: Revenue ($m), AGR (%), 2013-2017
  • Table 13.26: Regenerys Ltd.: Overview, 2019
  • Table 13.27: Regenerys Ltd.: Regenerative Medicine Clinical Trials, 2018
  • Table 13.28: Takeda Pharmaceutical Company Limited.: Overview, 2019
  • Table 13.29: Takeda Pharmaceutical Company Limited: Revenue ($m), AGR (%), 2013-2017
  • Table 13.30: Takeda Pharmaceutical Company Limited: Regenerative Medicine Clinical Trials, 2018
  • Table 13.31: UniQure N.V..: Overview, 2019
  • Table 13.32: UniQure N.V.: Revenue ($m), AGR (%), 2013-2017
  • Table 13.33: UniQure N.V.: Regenerative Medicine Clinical Trials, 2018
  • Table 13.34: Vericel Corporation.: Overview, 2019
  • Table 13.35: Vericel Corporation: Revenue ($m), AGR (%), 2013-2017
  • Table 13.36: Vericel Corporation: Regenerative Medicine Clinical Trials, 2018
  • Table 14.1: SWOT Analysis of the Global Translational Regenerative Medicine Market, 2019-2029
  • Table 15.1: Global Translational Regenerative Medicine Market Forecast: Revenue ($m), and CAGR (%), 2017, 2023 and 2029
  • Table 15.2: Global Translational Regenerative Medicine Market by Sector: CAGR (%), 2017, 2023, 2029
  • Table 15.3: Global Translational Regenerative Medicine Market by Region: CAGR (%), 2017, 2023, 2029
  • Table 15.4: Global Translational Regenerative Medicine Market: Products in Late Stage Development, 2018

List of Figures

  • Figure 1.1: Global Translational Regenerative Medicine Market Segmentation Overview
  • Figure 2.1: Brief History of Stem Cell Research, 1900-2019
  • Figure 2.2: Examples of FDA-Approved Tissue Engineering Products
  • Figure 2.3: Brief History of Tissue Engineering, 1900-2019
  • Figure 2.4: Brief History of Gene Therapy, 1970-2019
  • Figure 3.1: The Global Translational Regenerative Medicine Market Forecast by Sector: Revenue ($m), 2017 and 2018
  • Figure 3.2: The Global Translational Regenerative Medicine Market Forecast: Revenue ($m), 2017 and 2018
  • Figure 3.3: Global Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%), 2017-2029
  • Figure 3.4: The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2019-2023
  • Figure 3.5: The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2023-2029
  • Figure 3.6: The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2019-2029
  • Figure 3.7: The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2018, 2023 and 2029
  • Figure 3.8: The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2018
  • Figure 3.9: The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2023
  • Figure 3.10: The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2029
  • Figure 4.1: Global Stem Cell Therapies Market Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 4.2: Osteocel Plus Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 4.3: Trinity ELITE Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 4.4: TEMCELL / Prochymal Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 4.5: Stem Cell Therapies: Drivers and Restraints
  • Figure 5.1: Global Tissue Engineering Therapies Market Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 5.2: Apligraf Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 5.3: Dermagraft Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 5.4: Epifix Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 5.5: ReCell Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 5.6: Tissue Engineered Therapy: Drivers and Restraints
  • Figure 6.1: Global Gene Therapies Market Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 6.2: Neovasculgen Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 6.3: Glybera Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 6.4: Talimogene Laherparepvec (IMLYGIC) Sales Forecast: Revenue ($m) and AGR (%), 2019-2029
  • Figure 6.5: Gene Therapy: Drivers and Restraints
  • Figure 7.1: World Translational Regenerative Medicine Market: Revenues ($m) by Region, 2017
  • Figure 7.2: World Translational Regenerative Medicine Market: Revenues ($m) by Region, 2018
  • Figure 7.3: Global Translational Regenerative Medicine Market Forecast: Revenue ($m), AGR (%), 2017-2029
  • Figure 7.4: World Translational Regenerative Medicine Market: Market Shares (%) by Regional Market, 2017
  • Figure 7.5: World Translational Regenerative Medicine Market: Market Shares (%) by Regional Market, 2023
  • Figure 7.6: World Translational Regenerative Medicine Market: Market Shares (%) by Regional Market, 2029
  • Figure 8.1: North America Translational Regenerative Medicine Market Forecast: Revenues ($ m), AGR (%), 2017-2029
  • Figure 8.2: North America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2017
  • Figure 8.3: North America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2023
  • Figure 8.4: North America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2029
  • Figure 8.5: North America Translational Regenerative Medicine: Drivers and Restraints
  • Figure 8.6: U.S. Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 8.7: Canada Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 9.1: Europe Translational Regenerative Medicine: Drivers and Restraints
  • Figure 9.2: Europe Translational Regenerative Medicine Market: Revenues ($m) by Country/Sub-region, 2017
  • Figure 9.3: Europe Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 9.4: Europe Translational Regenerative Medicine Market: Market Shares (%) by Country, 2017
  • Figure 9.5: Europe Translational Regenerative Medicine Market: Market Shares (%) by Country, 2023
  • Figure 9.6: Europe Translational Regenerative Medicine Market: Market Shares (%) by Country, 2029
  • Figure 9.7: Germany Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 9.8: France Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 9.9: U.K. Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 9.10: Italy Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 9.11: Spain Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 9.12: Rest of Europe Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 10.1: Asia-Pacific Translational Regenerative Medicine: Drivers and Restraints
  • Figure 10.2: Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 10.3: Asia-Pacific Translational Regenerative Medicine Market: Market Shares (%) by Country, 2017
  • Figure 10.4: Asia-Pacific Translational Regenerative Medicine Market: Market Shares (%) by Country, 2023
  • Figure 10.5: Asia-Pacific Translational Regenerative Medicine Market: Market Shares (%) by Country, 2029
  • Figure 10.6: China Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 10.7: Japan Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 10.8: India Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 10.9: Rest of Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 11.1: Latin America Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 11.2: Latin America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2017
  • Figure 11.3: Latin America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2023
  • Figure 11.4: Latin America Translational Regenerative Medicine Market: Market Shares (%) by Country, 2029
  • Figure 11.5: Brazil Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 11.6: Mexico Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 11.7: Rest of Latin America Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 12.1: Middle East & Africa (MEA) Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 12.2: Middle East & Africa Translational Regenerative Medicine Market: Market Shares (%) by Country, 2017
  • Figure 12.3: Middle East & Africa Translational Regenerative Medicine Market: Market Shares (%) by Country, 2023
  • Figure 12.4: Middle East & Africa Translational Regenerative Medicine Market: Market Shares (%) by Country, 2029
  • Figure 12.5: GCC Countries Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 12.6: South Africa Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 12.7: Rest of MEA Translational Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), 2017-2029
  • Figure 13.1: Athersys, Inc.: Revenue ($m), AGR (%), 2013-2017
  • Figure 13.2: Athersys, Inc.: Business Segment Revenue Share (%), 2017
  • Figure 13.3: Avita Medical: Revenue ($m), AGR (%), 2014-2018
  • Figure 13.4: Avita Medical: Business Segment Revenue Share (%), 2017
  • Figure 13.5: AxoGen, Inc.: Revenue ($m), AGR (%), 2013-2017
  • Figure 13.6: MEDIPOST Co., Ltd.: Revenue ($m), AGR (%), 2013-2017
  • Figure 13.7: MEDIPOST Co., Ltd.: Business Segment Revenue Share (%), 2017
  • Figure 13.8: NuVasive: Revenue ($m), AGR (%), 2013-2017
  • Figure 13.9: NuVasive: Business Segment Revenue Share (%), 2017
  • Figure 13.10: Astellas Pharma: Revenue ($m), AGR (%), 2013-2017
  • Figure 13.11: Astellas Pharma: Region Revenue Share (%), 2017
  • Figure 13.12: Osiris Therapeutics, Inc.: Revenue ($m), AGR (%), 2013-2017
  • Figure 13.13: Osiris Therapeutics, Inc.: Product Revenue Share (%), 2017
  • Figure 13.14: Pharmicell Co., Ltd.: Revenue ($m), AGR (%), 2013-2017
  • Figure 13.15: Takeda Pharmaceutical Company Limited: Revenue ($m), AGR (%), 2013-2017
  • Figure 13.16: Takeda Pharmaceutical Company Limited: Business Segment Revenue Share (%), 2017
  • Figure 13.17: Takeda Pharmaceutical Company Limited: Regional Revenue Share (%), 2017
  • Figure 13.18: UniQure N.V.: Revenue ($m), AGR (%), 2013-2017
  • Figure 13.19: Vericel Corporation: Revenue ($m), AGR (%), 2013-2017
  • Figure 13.20: Vericel Corporation: Product Revenue Share (%), 2017
  • Figure 14.1: Porter's Five Force Analysis of the Translational Regenerative Medicine Market, 2019
  • Figure 15.1: Translational Regenerative Medicine Market Forecast by Sector: Revenue ($m), 2017-2029
  • Figure 15.2: Global Translational Regenerative Medicine Market Forecast: Revenue ($m) 2017, 2023, 2029
  • Figure 15.3: Global Translational Regenerative Medicine Drugs Market by Sector: Market Share (%), 2018
  • Figure 15.4: Global Translational Regenerative Medicine Drugs Market by Sector: Market Share (%), 2023
  • Figure 15.5: Global Translational Regenerative Medicine Drugs Market by Sector: Market Share (%), 2029
  • Figure 15.6: The Global Translational Regenerative Medicine Market Forecast by Region: Revenue (US$ Bn), 2017, 2023, 2029

COMPANIES LISTED:

  • Aastrom Biosciences, Inc.
  • Abeona Therapeutics Inc.
  • Advantagene
  • Ageless Regenerative Institute
  • Alliqua BioMedical, Inc.
  • AlloSource
  • AlphaTecSpine
  • Altrika
  • Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
  • AnGes MG/ Vical
  • Anterogen
  • Arizona Pain Specialists
  • Assistance Publique Hopitaux De Marseille
  • Astellas Pharma
  • Athersys, Inc.
  • Avita Medical
  • Axiogenesis AG
  • AxoGen, Inc.
  • Baxter
  • Bellicum Pharmaceuticals
  • Benda Pharmaceutical
  • Biedermann Technologies GmbH & Co. KG
  • BioCardia, Inc.
  • Bioheart
  • bluebird bio
  • BrainStorm Cell Therapeutics
  • Bristol-Meyers Squibb
  • Caladrius Biosciences
  • Capricor
  • Cardio3 BioSciences
  • Celgene
  • Cell Medica
  • Cellerant Therapeutics
  • Cellular Dynamics International, Inc.
  • Ceregene
  • Chiesi Farmaceutici SpA
  • Cold Genesys
  • Cytori Therapeutics
  • DePuy Mitek
  • Dimension Therapeutics, Inc.
  • Fibrocell Science
  • FUJIFILM Corporation
  • GE Healthcare
  • Genzyme
  • Healeon Medical Inc
  • HEALIOS K.K.
  • Hemostemix
  • Hoffmann-La Roche
  • Homology Medicines, Inc.
  • Innovative Cellular Therapeutics (ICT)
  • Integra LifeSciences
  • Intrexon
  • Invetech
  • Irvine Scientific
  • Japan Regenerative Medicine Co., Ltd.
  • Japan Tissue Engineering Co. Ltd
  • JCR Pharmaceuticals Co. Ltd.
  • Jianwu Dai
  • Johnson & Johnson
  • Kinetic Concepts Inc
  • Kite Pharma
  • Lonza Houston, Inc.
  • MacroCure
  • Medipost
  • MediStem
  • Medtronic
  • Mesoblast, Ltd.
  • MidCap Financial Services (MidCap Financial)
  • MiMedx Group, Inc.
  • Nasser Aghdami MD., PhD
  • Novartis
  • NuVasive
  • Ocata Therapeutics
  • OhioHealth
  • Orchard Therapeutics
  • Organogenesis Holdings Inc.
  • Orthofix
  • Osiris Therapeutics, Inc.
  • Oxford BioMedica
  • Pall Corporation
  • Parcell Laboratories
  • Pfizer, Inc.
  • Pharmaceutical
  • Pharmicell Co., Ltd.
  • Promethera Biosciences SA
  • Regen Lab SA
  • Regenerative Patch Technologies, LLC
  • Regenerative Sciences, LLC
  • Regenerys Ltd.
  • Regeneus
  • ReNeuron
  • Royan Institute
  • Sangamo BioSciences
  • Sanofi
  • Semma Therapeutics
  • Servier
  • Shanghai Sunway
  • Shinya Yamanaka
  • Siemens Healthineers
  • Silicon Valley Bank
  • Skye Orthobiologics
  • Sobi Partners
  • Sotex PharmFirm
  • Spark Therapeutics
  • StemCells Inc.
  • Stempeutics Research
  • Takeda Pharmaceuticals
  • TiGenix
  • TissueGene, Inc.
  • U.S. Stem Cell Inc.
  • uniQure NV
  • Universal Cells, Inc.
  • Vericel Corporation
  • ViaCyte Inc
  • Xenetic Biosciences
  • Zimmer

List of Organisations Mentioned in This Report:

  • Academy Military Medical Science, China
  • American Diabetes Association
  • Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
  • Arthritis Research UK
  • Australian Regenerative Medicine Institute
  • Australian Research Council
  • Banc de Sang i Teixits
  • Beijing Cancer Hospital
  • Brazil Ministry of Health, Ministry of Education
  • Brazilian Development Bank (BNDES)
  • British Heart Foundation
  • Cambridge University Hospitals NHS Foundation Trust
  • Catalan Institution for Research and Advanced Studies
  • Center for Biologics Evaluation and Research (CBER)
  • Center for Devices and Radiological Health (CDRH).
  • Center for Drug Evaluation and Research (CDER)
  • Centre Hospitalier René Dubos
  • Charité University Clinic
  • China Construction bank
  • Chinese Academy of Sciences
  • Committee for Advanced Therapies
  • Committee for Medicinal Products for Human Use (CHMP)
  • Department of Health and the Care Quality Commission
  • Drugs Controller General of India
  • European Commission
  • European Group for Blood and Marrow Transplantation
  • European Medicines Agency
  • European Patent Office
  • European Union
  • Food and Drug Administration (FDA)
  • Fourth Military Medical University
  • German National Registry of Blood Stem Cell Donors
  • Herlev Hospital
  • House of Lords Science and Technology Committee
  • Human Fertilisation and Embryology Authority
  • Human Stem Cell Institute
  • Innovation in Japan
  • Institute for Biomedical Research
  • Kenneth Hargreaves
  • King Abdullah International Medical Research Centre (KAIMRC)
  • King Khaled University
  • King Saud bin Abdulaziz University for Health Sciences (KSAU - HS)
  • Korea Food and Drug Administration
  • Kuopio University Hospital
  • Massachusetts General Hospital (MGH)
  • Medical Research Council
  • Ministry of Food and Drug Safety
  • Ministry of Public Health, Republic of Belarus
  • Musculoskeletal Transplant Foundation (MTF)
  • Northwestern University
  • Nursing Association for the Study of Cutaneous Wounds
  • Oregon Health and Science University
  • Pharmaceuticals and Medical Devices Agency (PMDA)
  • Regenerative Medicines in Europe Project (REMEDiE)
  • Russian Academy of Medical Sciences
  • Russian Ministry of Healthcare and Social Development
  • Servizio Sanitario Nazionale, Italy
  • Sidney Kimmel Comprehensive Cancer Center
  • South African Government
  • South China Research Center for Stem Cell and Regenerative Medicine
  • Stanford University
  • State Food and Drug Administration
  • The University of Texas Health Science Center, Houston
  • Therapeutics Goods Administration
  • University College London
  • University Hospital of Basel, Switzerland
  • University of California, Los Angeles (UCLA)
  • University of California, San Francisco (UCSF)
  • University of Leeds
  • University of Massachusetts
  • Wenzhou Medical University
  • World Bank
  • Yamaguchi University Hospital
目次
Product Code: PHA0354

The Global Translational Regenerative Medicine market is estimated to grow at a CAGR of 23.3% in the first half of the forecast period. Stem cell therapies accounted for the majority of the revenue in the market with an estimated market share of 57.7% in 2018.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you will find 334-page report and you will receive 119 tables and 106 figures - all unavailable elsewhere.

The 334-page report provides clear detailed insight into the Global Translational Regenerative Medicine market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Translational Regenerative Medicine market forecasts from 2019-2029.

Global Translational Regenerative Medicine submarket forecasts from 2019-2029 covering:

  • Stem Cell Therapies
  • Tissue Engineered Products
  • Gene Therapies

This study discusses the late-state clinical trials and pipeline as well as market drivers and restraints of each submarket.

Translational Regenerative Medicine regional and national market forecasts from 2019-2029, covering:

  • North America: US, Canada
  • Europe: Germany, France, UK, Italy, Spain, Rest of Europe
  • Asia-Pacific: China, Japan, India, Rest of Asia-Pacific
  • Latin America: Brazil, Mexico, Rest of Latin America
  • Middle East & Africa: GCC Countries, South Africa, Rest of Middle East & Africa

Each regional market is further segmented by sector.

Forecasts from 2019-2029 of the selected leading products in the Global Translational Regenerative Medicine market:

  • Osteocel Plus
  • Trinity ELITE
  • TEMCELL /Prochymal
  • Apligraf
  • Dermagraft
  • Epifix
  • ReCell
  • Neovasculgen
  • Glybera (alipogene tiparvovec)
  • IMLYGIC (talimogene laherparepvec)

Assessment of the leading companies in the Global Translational Regenerative Medicine market:

  • Athersys, Inc.
  • Avita Medical
  • AxoGen, Inc.
  • MEDIPOST Co., Ltd.
  • NuVasive
  • Astellas Pharma
  • Organogenesis Holdings Inc.
  • Osiris Therapeutics, Inc.
  • Pharmicell Co., Ltd.
  • Regenerys Ltd.
  • Takeda Pharmaceutical Company Limited
  • uniQure N.V. N.V.
  • Vericel Corporation

Information on current developments, current advancements and current key approvals in the field of translational regenerative medicine market.

SWOT and Porter's Five Force analysis of the translational regenerative medicine market.

Visiongain's study is intended for anyone requiring commercial analyses for the Translational Regenerative Medicine Market and leading companies. You find data, trends and predictions.

Buy our report today Translational Regenerative Medicine Market Forecast 2019-2029: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Translational Regenerative Medicine Market Overview
  • 1.2. Overview of Findings
  • 1.3. Structure of the Report
  • 1.4. Global Translational Regenerative Medicine Market Segmentation
  • 1.5. Why You Should Read This Report
  • 1.6. How This Report Delivers
  • 1.7. Key Questions Answered by This Analytical Report
  • 1.8. Who is This Report For?
  • 1.9. Methodology
  • 1.10. Associated Visiongain Reports
  • 1.11. About Visiongain

2. Introduction to Translational Regenerative Medicine

  • 2.1. What is Regenerative Medicine?
    • 2.1.1. Translational Regenerative Medicine - From Bench to Bedside
  • 2.2. Translational Regenerative Medicine - Market Breakdown
    • 2.2.1. Stem Cell Therapy - Marketable Differentiation and Specialisation
      • 2.2.1.1. How Embryonic Stem Cells(ESCs) Entered the Fray
      • 2.2.1.2. Classifying Stem Cells by Potency
      • 2.2.1.3. Stem Cells Categories: ESCs, SSCs, iPSCs
      • 2.2.1.4. Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
      • 2.2.1.5. Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products?
    • 2.2.2. Tissue Engineering - In Vitro Manipulation for Therapeutic Purposes
    • 2.2.3. Gene Therapies
      • 2.2.3.1. Harnessing Infectivity: Viral Vectors in Gene Therapy
  • 2.3. Other Approaches to Regenerative Medicine
    • 2.3.1. Small Molecules and Proteins - Scaffold-Based Delivery of Signalling Molecules
    • 2.3.2. Cosmetic Applications of Regenerative Medicine
  • 2.4. Regulation of Regenerative Medicine
    • 2.4.1. Regulation of Regenerative Medicine Products in Europe
    • 2.4.2. Regulation of Regenerative Medicine Products in the US
  • 2.5. The Phases of Clinical Trials
  • 2.6. Market Definition
    • 2.6.1. Products Excluded from the Report

3. Translational Regenerative Medicine Market, 2019-2029

  • 3.1. Global Translational Regenerative Medicine: Market Overview
    • 3.1.1. Segments within the Global Translational Regenerative Medicine Market
  • 3.2. The Global Translational Regenerative Medicine Market in 2017 and 2018
  • 3.3. Global Translational Regenerative Medicine: Market Forecast 2019-2029
    • 3.3.1. Market Sectors That Will Drive Translational Regenerative Medicine Growth
    • 3.3.2. Global Translational Regenerative Medicine Market - Changing Market Shares by Sector 2019-2029
    • 3.3.3. Global Translational Regenerative Medicine Market - Current Developments in the Field, 2016, 2017 & 2018

4. Stem Cell Therapies: Leading Applications, 2019-2029

  • 4.1. The Global Market for Stem Cell Therapies, 2017 and 2018
    • 4.1.1. Stem Cell Therapies: Currently Available Therapies
    • 4.1.2. Haematopoietic Stem Cell Transplantation(HSCT)
      • 4.1.2.1. HSCT for the Treatment of Multiple Sclerosis - A Possible Cure?
    • 4.1.3. Stem Cell Orthobiologics
  • 4.2. Stem Cell Therapies: Global Market Forecast 2019-2029
  • 4.3. AlloStem(AlloSource)
  • 4.4. Osteocel Plus(NuVasive)
    • 4.4.1. Osteocel Plus: Sales Forecast 2019-2029
  • 4.5. Trinity ELITE and Trinity Evolution(Orthofix)
    • 4.5.1. Trinity ELITE and Trinity Evolution: Sales Forecast, 2019-2029
  • 4.6. PureGen(AlphaTec Spine)
  • 4.7. Other Approved Stem Cell Therapy Products
    • 4.7.1. Cartistem(Medipost)
    • 4.7.2. Cupistem(Anterogen)
    • 4.7.3. Hearticellgram-AMI(Pharmicell)
    • 4.7.4. TEMCELL/ Prochymal/ Remestemcel-L(Mesoblast)
      • 4.7.4.1. TEMCELL/ Prochymal(Remestemcel-L): Sales Forecast 2019-2029
  • 4.8. Development Pipeline for Stem Cell Therapies, 2019-2029
    • 4.8.1. Late-Stage Pipeline for Stem Cell Therapies, 2018
      • 4.8.1.1. StemEx and NiCord(Gamida Cell)
        • 4.8.1.1.1. StemEx Shows Improved Survival at 100 Days - but FDA Wants Another Clinical Trial
      • 4.8.1.2. Copper Chelator Based Technology
      • 4.8.1.3. NiCord
        • 4.8.1.3.1. NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA
        • 4.8.1.3.2. NAM Technology Platform
      • 4.8.1.4. Mesenchymal Precursor Cell Therapies(Mesoblast)
      • 4.8.1.5. Adult Autologous CD34+ Cells(Baxter)
      • 4.8.1.6. MyoCell(U.S. Stem Cell Inc.)
      • 4.8.1.7. Adipocell(Bioheart)
      • 4.8.1.8. Cx601(TiGenix)
      • 4.8.1.9. Adipose-Derived Stem Cells(Cytori Therapeutics)
      • 4.8.1.10. Stempeucel(Stempeutics Research)
      • 4.8.1.11. C-Cure(Cardio3 BioSciences)
      • 4.8.1.12. Other Late-Stage Stem Cell Therapies
    • 4.8.2. Diabetes and Stem Cell Therapy
      • 4.8.2.1. Mesenchymal Precursor Cells(Mesoblast)
      • 4.8.2.2. VC-01(ViaCyte Inc)
        • 4.8.2.2.1. Clinical Development Efforts for VC-01 for the Treatment of Diabetes
    • 4.8.3. Cardiovascular Disease and Stem Cell Therapy
      • 4.8.3.1. Endometrial Regenerative Cells(MediStem, Intrexon)
      • 4.8.3.2. AMR-001(Caladrius Biosciences)
      • 4.8.3.3. CAP-1002(Capricor)
    • 4.8.4. Stem Cell Therapy in Cancer
      • 4.8.4.1. CLT-008(Cellerant Therapeutics)
      • 4.8.4.2. OncoCyte/BioTime - Targeting Cancer with Gene and Stem Cell Therapy
    • 4.8.5. Stem Cell Therapy for Central Nervous System(CNS) Conditions
      • 4.8.5.1. NurOwn(BrainStorm Cell Therapeutics)
        • 4.8.5.1.1. Clinical Development Efforts for NurOwn, 2015
      • 4.8.5.2. NSI-566(Neuralstem)
      • 4.8.5.3. NSI-189(Neuralstem)
      • 4.8.5.4. MultiStem(Athersys)
      • 4.8.5.5. PDA-001(Cenplacel-L, Celgene)
      • 4.8.5.6. ALD-401(Cytomedix)
      • 4.8.5.7. ReN001(ReNeuron)
    • 4.8.6. Stem Cell Therapy for Eye Diseases
      • 4.8.6.1. MA09-hRPE(Ocata Therapeutics)
      • 4.8.6.2. HuCNS-SC(StemCells Inc.)
      • 4.8.6.3. Collaboration and License Agreement Between Pfizer And The London Project to Cure Blindness
  • 4.9. ChondroCelect(TiGenix BV)
  • 4.10. Stem Cells Therapy Market: Drivers and Restraints 2019-2029

5. Tissue Engineering Therapies: Leading Applications, 2019-2029

  • 5.1. The Global Market for Tissue Engineered Therapies, 2017
    • 5.1.1. Tissue Engineering Therapies: Currently Available Therapies
  • 5.2. Tissue Engineering Therapies: Global Market Forecast 2019-2029
  • 5.3. Tissue Engineering in Wound Repair and Healing
    • 5.3.1. Apligraf(Organogenesis)
      • 5.3.1.1. Apligraf: Historical Sales Analysis
      • 5.3.1.2. Apligraf: Sales Forecast 2019-2029
    • 5.3.2. BioDfence and BioDfactor(BioD)
    • 5.3.3. CureXcell(MacroCure)
    • 5.3.4. Dermagraft(Organogenesis)
      • 5.3.4.1. Dermagraft(Organogenesis): Sales Forecast 2019-2029
    • 5.3.5. Epifix(MiMedx)
      • 5.3.5.1. Epifix(MiMedx): Sales Forecast 2019-2029
    • 5.3.6. Epicel(Vericel)
    • 5.3.7. Grafix(Osiris Therapeutics)
    • 5.3.8. MySkin and CyroSkin(Regenerys)
    • 5.3.9. ReCell(Avita Medical)
      • 5.3.9.1. ReCell(Avita Medical): Sales Forecast 2019-2029
  • 5.4. Tissue Engineering for Cartilage Repair
    • 5.4.1. Autologous Chondrocyte Implantation(ACI)
    • 5.4.2. Carticel(Vericel Corp.)
    • 5.4.3. ChondroCelect(TiGenix, Sobi Partners)
    • 5.4.4. DeNovo NT(Zimmer)
    • 5.4.5. MACI(Vericel Corp.)
  • 5.5. Other Available Tissue Engineering Therapies
    • 5.5.1. Autologous Cultured Cell and Tissue Products(Japan Tissue Engineering Co.)
    • 5.5.2. Gintuit(Organogenesis)
    • 5.5.3. LAVIV(azficel-T),(Fibrocell Science)
    • 5.5.4. Acellular Tissue Engineering Products
  • 5.6. Tissue Engineering: Development Pipeline, 2019-2029
    • 5.6.1. Pipeline Products for Autologous Chondrocyte Implantation
    • 5.6.2. Tissue Engineering for Skin
    • 5.6.3. Tissue Engineering for Liver Diseases
      • 5.6.3.1. Extracorporeal Bio-Artificial Liver Therapy(Vital Therapies)
    • 5.6.4. Tissue Engineering for Cardiovascular Disease
    • 5.6.5. Tissue Engineering for Eye Diseases
  • 5.7. Future Prospects for Organ Transplantation and Tissue Engineering
  • 5.8. Tissue Engineered Products Market: Drivers and Restraints 2019-2029

6. Gene Therapies: Leading Applications, 2019-2029

  • 6.1. The Global Market for Gene Therapies, 2017
  • 6.2. Gene Therapies: Global Market Forecast 2019-2029
  • 6.3. Currently Available Gene Therapy Products
    • 6.3.1. Gendicine(Benda Pharmaceutical)
    • 6.3.2. Oncorine(Shanghai Sunway Biotech)
    • 6.3.3. Neovasculgen(Human Stem Cells Institute)
      • 6.3.3.1. Neovasculgen(HSCI): Sales Forecast 2019-2029
    • 6.3.4. Glybera(UniQure N.V.)
    • 6.3.5. IMLYGIC(talimogene laherparepvec) -(Amgen)
      • 6.3.5.1. Clinical Trials and Development Efforts for IMLYGIC
      • 6.3.5.2. Talimogene Laherparepvec(IMLYGIC) - Sales Forecast 2019-2029
  • 6.4. Development Pipeline for Gene Therapies, 2019-2029
    • 6.4.1. Late-Stage Pipeline Gene Therapies, 2018
      • 6.4.1.1. Collategene(beperminogene perplasmid, AMG0001) -(AnGes MG/Vical)
      • 6.4.1.2. ProstAtak(AdV-tk) -(Advantagene)
      • 6.4.1.3. Trinam(taberminogene vadenovec) -(Ark Therapeutics)
      • 6.4.1.4. AAV2-hRPE65v2(Spark Therapeutics)
      • 6.4.1.5. CG0070(Cold Genesys)
    • 6.4.2. Gene Therapy for Use in the Treatment of Diabetes
    • 6.4.3. Gene Therapy Directed at Oncology Indications
    • 6.4.4. Gene Therapy Directed at Neurological Diseases
    • 6.4.5. Gene Therapy Directed at Tackling Haemophilia B
  • 6.5. Gene Therapy Market: Drivers and Restraints 2019-2029

7. Leading National Markets 2019-2029

  • 7.1. The Translational Regenerative Medicine Market by Region
  • 7.2. World Translational Regenerative Medicine Market: Regional Forecast 2019-2029
    • 7.2.1. How Will Regional Market Shares Change to 2029?

8. North America Translational Regenerative Medicine Market 2019-2029

  • 8.1. US Translational Regenerative Medicine Market: Market Forecast 2019-2029
    • 8.1.1. US Translational Regenerative Medicine Market: Market Drivers and Restraints, 2019-2029
    • 8.1.2. US Translational Regenerative Medicine Market: Market Forecast 2019-2029
    • 8.1.3. The Regulatory Framework for Regenerative Medicine in the US
    • 8.1.4. The Impact of Ethical and Regulatory Reluctance to Embryonic Stem Cell Research and Its Impact on Funding
    • 8.1.5. How Is the Ending of Patenting for Human Gene Products Affecting the Regenerative Medicine Market in the US?
  • 8.2. Canada Translational Regenerative Medicine Market: Trends and Developments

9. Europe Translational Regenerative Medicine Market 2019-2029

  • 9.1. Europe: A Fragmented Regenerative Medicine Market
    • 9.1.1. European Regenerative Medicine Market: Market Drivers and Restraints, 2019-2029
    • 9.1.2. European Regenerative Medicine Market: Market Forecast 2019-2029
  • 9.2. Europe Markets: Changing Market Shares by Country, 2019-2029
    • 9.2.1. Europe's Unitary Patent System and Its Impact on the Future of Regenerative Medicine in the Region
    • 9.2.2. Regulation of Regenerative Medicine in the European Union
  • 9.3. Germany
    • 9.3.1. German Translational Regenerative Medicine Market: Market Forecast 2019-2029
  • 9.4. France Translational Regenerative Medicine Market Forecast 2019-2029
  • 9.5. U.K.
    • 9.5.1. U.K. Translational Regenerative Medicine Market Forecast 2019-2029
    • 9.5.2. Regulation of Stem Cell Research in the UK
  • 9.6. Italy
    • 9.6.1. Italy Translational Regenerative Medicine Market Forecast 2019-2029
  • 9.7. Spain Translational Regenerative Medicine Market Forecast 2019-2029
  • 9.8. Rest of Europe Translational Regenerative Medicine Market Forecast 2019-2029
    • 9.8.1. Russia: Rising Interest in Regenerative Medicine Research

10. Asia-Pacific Translational Regenerative Medicine Market 2019-2029

  • 10.1. Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation
    • 10.1.1. Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2019-2029
    • 10.1.2. Asia-Pacific Regenerative Medicine Market: Market Forecast 2019-2029
  • 10.3. China: Encouraging Stem Cell R&D
    • 10.3.1. Government Intervention into TRM Research in China
    • 10.3.2. Regulation of Stem Cell Research in China
    • 10.3.3. Commercialisation of Gene Therapy and Tissue Engineering Products in China
    • 10.3.4. Medical Tourism Impacting Market Growth for Regenerative Medicine in China
    • 10.3.5. China Translational Regenerative Medicine Market Forecast 2019-2029
  • 10.4. Japan: Difficulty in Translating Research into Commercialisation
    • 10.4.1. Research Funding: A Major Determinant of Growth in Japan's Regenerative Medicine
    • 10.4.2. Government Interventions in Promoting Stem Cell Research in Japan
    • 10.4.3. Regulation of Regenerative Medicine in Japan
    • 10.4.4. Accelerating Approvals of Regenerative Medicine Products in Japan
    • 10.4.5. Japanese Translational Regenerative Medicine Market Forecast 2019-2029
  • 10.5. India: An Emerging Market for Regenerative Medicine
    • 10.5.1. Efforts in Stem Cell Research in India
    • 10.5.2. Unclear Guidelines Hindering Progression of Gene Therapy Research in India
    • 10.5.3. India Translational Regenerative Medicine Market Forecast 2019-2029
  • 10.6. Rest of Asia-Pacific Translational Regenerative Medicine Market: Trends and Developments
    • 10.6.1. Australia: Encouraging Translational Regenerative Medicine
    • 10.6.2. South Korea: First to Approve Stem Cell Treatments
    • 10.6.3. A Regeneration in South Korea's Stem Cell Research Efforts
    • 10.6.4. Rest of Asia-Pacific Translational Regenerative Medicine Market Forecast 2019-2029

11. Latin America Translational Regenerative Medicine Market 2019-2029

  • 11.1. Brazil
    • 11.1.1. Brazil Translational Regenerative Medicine Market Forecast 2019-2029
      • 11.1.1.1. Stem cell initiatives in Brazil
      • 11.1.1.2. Stem cell regulation & strengths, weaknesses & opportunities in Brazil
  • 11.2. Mexico Translational Regenerative Medicine Market: Trends and Developments
    • 11.2.1. Stem cell initiatives in Mexico
    • 11.2.2. Stem cell regulation & strengths, weaknesses & opportunities in Mexico
  • 11.3. Rest of Latin America Translational Regenerative Medicine Market: Trends and Developments

12. Middle East & Africa Translational Regenerative Medicine Market 2019-2029

  • 12.1. GCC Countries Translational Regenerative Medicine Market Forecast 2019-2029
  • 12.2. South Africa Translational Regenerative Medicine Market Forecast 2019-2029
  • 12.3. Rest of Middle East & Africa Translational Regenerative Medicine Market Forecast 2019-2029

13. Leading Companies in the Translational Regenerative Medicine Market, 2019-2029

  • 13.1. Introduction to the Leading Companies
  • 13.2. Athersys, Inc.
    • 13.2.1. Overview
    • 13.2.2. Financial Overview
    • 13.2.3. Athersys: Pipeline Analysis, 2018
      • 13.2.3.1. MultiStem Technology - Potential Treatment for a Range of Diseases
    • 13.2.4. Recent Transactions Summary
  • 13.3. Avita Medical
    • 13.3.1. Overview
    • 13.3.2. Financial Overview
    • 13.3.3. Avita Medical: Regenerative Medicine Portfolio, 2018
    • 13.3.4. Avita Medical: Pipeline Analysis, 2018
    • 13.3.5. Recent Transactions Summary
  • 13.4. AxoGen, Inc.
    • 13.4.1. Overview
    • 13.4.2. Financial Overview
    • 13.4.3. AxoGen, Inc.: Regenerative Medicine Portfolio, 2018
    • 13.4.4. AxoGen, Inc.: Pipeline Analysis, 2018
    • 13.4.5. Recent Transactions Summary
  • 13.5. MEDIPOST Co., Ltd.
    • 13.5.1. Overview
    • 13.5.2. Financial Overview
    • 13.5.3. MEDIPOST Co., Ltd.: Regenerative Medicine Portfolio, 2018
    • 13.5.4. MEDIPOST Co., Ltd.: Pipeline Analysis, 2018
    • 13.5.5. Recent Transactions Summary
  • 13.6. NuVasive
    • 13.6.1. Overview
    • 13.6.2. Financial Overview
    • 13.6.3. NuVasive: Regenerative Medicine Portfolio, 2018
    • 13.6.4. NuVasive: Pipeline Analysis, 2018
    • 13.6.5. Recent Transactions Summary
  • 13.7. Astellas Pharma
    • 13.7.1. Overview
    • 13.7.2. Financial Overview
    • 13.7.3. Astellas Pharma(Ocata Therapeutics): Pipeline Analysis, 2018
      • 13.7.3.1. Retinal Pigment Epithelial Cell Therapy
      • 13.7.3.2. Ocata's Other Therapeutic Platforms
    • 13.7.4. Recent Transactions Summary
  • 13.8. Organogenesis Holdings Inc.
    • 13.8.1. Overview
    • 13.8.2. Organogenesis Holdings Inc.: Regenerative Medicine Portfolio, 2018
    • 13.8.3. Organogenesis Holdings Inc.: Pipeline Analysis, 2018
    • 13.8.4. Recent Transactions Summary
  • 13.9. Osiris Therapeutics, Inc.
    • 13.9.1. Overview
    • 13.9.2. Financial Overview
    • 13.9.3. Osiris Therapeutics, Inc.: Regenerative Medicine Portfolio, 2018
    • 13.9.4. Osiris Therapeutics, Inc.: Pipeline Analysis, 2018
    • 13.9.5. Recent Transactions Summary
  • 13.10. Pharmicell Co., Ltd.
    • 13.10.1. Overview
    • 13.10.2. Financial Overview
    • 13.10.3. Pharmicell Co., Ltd.: Pipeline Analysis, 2018
  • 13.11. Regenerys Ltd.
    • 13.11.1. Overview
    • 13.11.2. Regenerys Ltd.: Regenerative Medicine Portfolio, 2018
    • 13.11.3. Regenerys Ltd.: Pipeline Analysis, 2018
    • 13.11.4. Recent Transactions Summary
  • 13.12. Takeda Pharmaceutical Company Limited
    • 13.12.1. Overview
    • 13.12.2. Financial Overview
    • 13.12.3. Takeda Pharmaceutical Company Limited(TiGenix): Pipeline Analysis, 2018
    • 13.12.4. Recent Transactions Summary
  • 13.13. uniQure N.V. N.V.
    • 13.13.1. Overview
    • 13.13.2. Financial Overview
    • 13.13.3. UniQure N.V.: Pipeline Analysis, 2018
    • 13.13.4. Recent Transactions Summary
  • 13.14. Vericel Corporation
    • 13.14.1. Overview
    • 13.14.2. Financial Overview
    • 13.14.3. Vericel Regenerative Medicine Portfolio, 2018
    • 13.14.4. Vericel Corporation: Pipeline Analysis, 2018
      • 13.14.4.1. The ixCELL-DCM Clinical Trial
    • 13.14.5. Recent Transactions Summary

14. Qualitative Analysis of the Translational Regenerative Medicine Market, 2019-2029

  • 14.1. Market Factors Influencing the Translational Regenerative Medicine Market
  • 14.2. SWOT Analysis of the Translational Regenerative Medicine Market
    • 14.2.1. Strengths
      • 14.2.1.1. Improvements in Regulatory Frameworks
      • 14.2.1.2. Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine
      • 14.2.1.3. Strong Support from Governments in Multiple Regions
      • 14.2.1.4. Increasing Ease of Product Commercialisation and Market Access
    • 14.2.2. Weaknesses
      • 14.2.2.1. The High Price of Translational Regenerative Medicine Products May Restrain Market Growth
      • 14.2.2.2. Lack of Funding from Venture Capital
      • 14.2.2.3. The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing
      • 14.2.2.4. Successful Commercialisation of TRM Products Requires New Business Models
    • 14.2.3. Opportunities
      • 14.2.3.1. 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
      • 14.2.3.2. Medical Tourism May Stimulate Standardisation and Drive Market Growth
      • 14.2.3.3. Disruptive Translational Regenerative Medicine Therapies Can Create New Markets
    • 14.3.4. Threats
      • 14.3.4.1. Ethical Concerns Limiting R&D in Regenerative
      • 14.3.4.2. Difficulty Establishing Evidence Base for Long-Term Efficacy of TRM Therapies
      • 14.3.4.3. Rate of Scientific Progress - A Major Determinant of TRM Market Growth
      • 14.3.4.4. Restraints on Reimbursement May Slow Growth
  • 14.4. Porter's Five Force Analysis of the Translational Regenerative Medicine Market, 2019-2029
    • 14.4.1. Threat of New Entrants
    • 14.4.2. Threat of Substitutes
    • 14.4.3. Power of Suppliers
    • 14.4.4. Power of Buyers
    • 14.4.5. Rivalry among Competitors

15. Conclusions

  • 15.1. Overview of Current Market Conditions and Market Forecast, 2019-2029
  • 15.2. Stem Cell Therapies Will Remain as the Dominant Submarket
  • 15.3. Leading Regions in the Translational Regenerative Medicine Market in 2018
  • 15.4. R&D Pipeline Products Crucial to Future Market Growth
  • 15.5. What Does the Future Hold for Regenerative Medicine?
  • Appendices
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form
Back to Top